Contineum Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-59.98	-42.26	22.72	-24.25	-29
Depreciation & Amortization	0.32	0.26	0.2	0.33	0.33
Other Amortization	-	-	-	-	0.15
Loss (Gain) From Sale of Assets	0.07	-0.02	-	0	-
Loss (Gain) From Sale of Investments	-0.8	-3.95	-2.66	0.25	0.39
Stock-Based Compensation	10.04	6.8	2.22	1.93	1.75
Other Operating Activities	1.08	0.98	-2.11	2.9	0.01
Change in Accounts Payable	-0.87	1.14	-	-0.23	-0.11
Change in Other Net Operating Assets	-5.17	4.19	-1.02	-1.04	0.22
Operating Cash Flow	-55.31	-32.85	19.35	-20.12	-26.27
Capital Expenditures	-0.23	-0.51	-0.41	-0.12	-0.17
Sale of Property, Plant & Equipment	-	0.02	-	-	-
Investment in Securities	-3.48	-69.25	-65.15	22.42	-64.8
Investing Cash Flow	-3.71	-69.74	-65.57	22.3	-64.97
Long-Term Debt Repaid	-	-	-3.75	-1.25	-
Net Debt Issued (Repaid)	-	-	-3.75	-1.25	-
Issuance of Common Stock	112.94	109	0.16	0.02	0.11
Repurchase of Common Stock	-	-	-0.03	-0	-
Other Financing Activities	-0.26	-	-0.34	-	-
Financing Cash Flow	112.69	109	56.18	-1.24	79.84
Net Cash Flow	53.66	6.42	9.96	0.94	-11.4
Free Cash Flow	-55.54	-33.36	18.94	-20.24	-26.43
Free Cash Flow Margin	-	-	37.87%	-	-
Free Cash Flow Per Share	-2.00	-1.72	5.58	-9.02	-12.53
Cash Interest Paid	-	-	0.15	0.23	0.22
Cash Income Tax Paid	-	-	0.45	-	-
Levered Free Cash Flow	-36.92	-20.87	13.08	-12.61	-
Unlevered Free Cash Flow	-36.92	-20.87	13.21	-12.37	-
Change in Working Capital	-6.04	5.33	-1.02	-1.27	0.11

Source: S&P Capital IQ. Standard template. Financial Sources.